<table>
<thead>
<tr>
<th>Data Category</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Registry and Trial Identifying Number</td>
<td>ClinicalTrials.gov NCT01724099</td>
</tr>
<tr>
<td>Date of Registration in Primary Registry</td>
<td>November 2, 2012</td>
</tr>
<tr>
<td>Secondary Identifying Numbers</td>
<td>CCRG_2012_HP001</td>
</tr>
<tr>
<td>Source(s) of Monetary or Material Support</td>
<td>Korea Health Industry Development Institute</td>
</tr>
<tr>
<td>Primary Sponsor</td>
<td>Korea Health Industry Development Institute</td>
</tr>
<tr>
<td>Secondary Sponsor(s)</td>
<td>NA</td>
</tr>
<tr>
<td>Contact for Public Queries</td>
<td>Chunhoo Cheon, KMD 82-2-961-9278 <a href="mailto:Hreedom35@gmail.com">Hreedom35@gmail.com</a></td>
</tr>
<tr>
<td>Contact for Scientific Queries</td>
<td>Seong-Gyu Ko, MD, Ph.D, MPH 82-2-961-0329 <a href="mailto:epiko@khu.ac.kr">epiko@khu.ac.kr</a></td>
</tr>
<tr>
<td>Public Title</td>
<td>Evaluating Safety and Efficacy of Euiiyin-tang on Obesity</td>
</tr>
<tr>
<td>Scientific Title</td>
<td>Evaluating Safety and Efficacy of Euiiyin-tang on Obesity: study protocol for a randomized controlled trial</td>
</tr>
<tr>
<td>Countries of Recruitment</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>Health Condition(s) or Problem(s) Studied</td>
<td>Obesity</td>
</tr>
<tr>
<td>Intervention(s)</td>
<td>Active comparator: Euiiyin-tang Placebo comparator: Placebo</td>
</tr>
<tr>
<td>Key Inclusion and Exclusion Criteria</td>
<td>Inclusion Criteria:</td>
</tr>
<tr>
<td></td>
<td>Women aged 18-65 years old Patients applying to one of the followings 2.1. BMI 30kg/m2 or over 2.2. BMI 27-29.9kg/m2 with hypertension in a proper treatment and blood pressure controlled (SBP ≤ 145mmHg, DBP ≤ 95mmHg) 2.3. BMI 27-29.9kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose &lt; 7.8mmol/L(140mg/dL) 2.4. BMI 27-29.9kg/m2 with hyperlipidemia in a proper treatment 2.5. BMI 27-39.9kg/m2 and Total cholesterol 236mg/dL or over or Triglyceride 150mg/dL or over at screening Agreed to low-calorie diet during the trial Written informed consent of the trial</td>
</tr>
<tr>
<td></td>
<td>Exclusion Criteria:</td>
</tr>
<tr>
<td></td>
<td>Endocrine disease such as hypothyroidism, Cushing’s syndrome, etc.</td>
</tr>
</tbody>
</table>
Heart disease (heart failure, angina pectoris, myocardial infarction)
Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
Malignant tumour or lung disease
Cholelithiasis
Severe renal disability (SCr > 2.0 mg/dL)
Severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)
Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8mmol/L (140 mg/dL) or over
Narrow angle glaucoma
History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
History of stroke or temporary ischemic cardioplegia
History or existence of eating disorder such as anorexia nervosa or bulimia nervosa, etc.
Use of medication that could have effect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medication having effect on absorption, metabolism, excretion)
Use of β--blocker or diuretic as hypertension medication within last 3 months
Use of medication for central nervous system or central active weight reduction medication
Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)
Difficult to measure anthropometric dimensions because of anatomical change such as resection
Surgical history for weight reduction; bariatric surgery, etc.
Unable to follow instructions of the trial as judged by investigator
Women who were pregnant, lactating, planning a pregnancy or women of childbearing age who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.) (Women of childbearing
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Interventional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation</td>
<td>randomized</td>
</tr>
<tr>
<td>Intervention model</td>
<td>parallel assignment</td>
</tr>
<tr>
<td>Masking</td>
<td>double blind (subject, investigator)</td>
</tr>
<tr>
<td>Date of First Enrollment</td>
<td>December 2012</td>
</tr>
<tr>
<td>Target Sample Size</td>
<td>160</td>
</tr>
<tr>
<td>Recruitment Status</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Primary Outcome(s)</td>
<td>Weight reduction</td>
</tr>
<tr>
<td>Key Secondary Outcomes</td>
<td>C-reactive protein, Blood pressure, Blood glucose,</td>
</tr>
<tr>
<td></td>
<td>Waist/hip ratio, Waist circumference,</td>
</tr>
<tr>
<td></td>
<td>Korean Obesity-related Quality of Life scale,</td>
</tr>
<tr>
<td></td>
<td>Korean version of Eating Attitudes Test-26</td>
</tr>
<tr>
<td></td>
<td>Total cholesterol, Triglyceride, Visceral fat area</td>
</tr>
</tbody>
</table>